Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0038362 (stomatitis)
 8,852 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

4-methyl-2-amino-pyridine-palladiumchlorid (IV) showed an inactivation of cell-free enveloped DNA and RNA viruses in serum-free saline such as vaccinia, pseudorabies, herpes type 1, Newcastle disease and influenza virus A/fowl plague, human influenza type A and B and vesicular stomatitis viruses, and adenovirus, a naked DNA virus, too. Picorna viruses were not inactivated, the inactivation of other viruses failed in medium with 10% serum. However the replication of enveloped viruses as checked with vaccinia and fowl plague viruses was inhibited, also when the compound was present only for 1 h after infection. Contrary to this the multiplication of adenovirus was depressed only with 90%. For the inactivation of viruses high concentrations were necessary than for the inhibition of replication. Therefore more than one kind of mode of action have to be taken into consideration.
 ...
PMID:[On the biological action of transition metal complexes. 2. The antiviral activity of 4-methyl-2-amino-pyridine-palladium-chloride (IV)]. 679 48

Pyrazine diazohydroxide (NSC-361456) was identified as an active congener of pyridine 2-diazohydroxide with enhanced stability under physiologic conditions. In this phase I study, 35 patients with advanced cancer received 62 courses of PZDH administered intravenously every 3 weeks at doses ranging from 15-608 mg/m2. The dose-limiting toxicity was myelosuppression and the maximal tolerated dose was 487 mg/m2. Hematologic toxicity was delayed and prolonged with median time to recovery about 5 weeks. Mild gastrointestinal toxicity in the form of nausea and vomiting was fairly common. Ondansetron was effective in reducing nausea and vomiting at higher dose levels. Other less common reactions included stomatitis, diarrhea, fatigue, alopecia, and mild abnormalities of renal function and hepatic enzymes. PZDH pharmacokinetics were characterized in 16 patients who received doses of 100-608 mg/m2. Plasma elimination was fit to one (12/16) or two (4/16) compartment model with a mean k10 half-life of 11.5 min. Clearance was dose dependent. Hematologic toxicity was related to PZDH dose, AUC and peak plasma concentration. The sigmoidal relationships between hematologic toxicity and AUC or peak plasma concentration were well described by the Hill equation. There were no objective responses observed in this study. Based on this study, the recommended dose for phase II evaluation of PZDH using this schedule is 390 mg/m2.
 ...
PMID:Pyrazine diazohydroxide (NSC-361456). Phase I clinical and pharmacokinetic studies. 789 39